Heat Biologics Statistics, Revenue Totals, Facts & News (2022)
Last Updated on: June 3rd, 2021
Here are a few of the most interesting Heat Biologics statistics and facts I was able to dig up including revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Heat Biologics Facts
- Website: Official Website
- Year Founded: 2008
- Headquarters: Durham, NC
- Founder(s): Jeffrey Wolf
- Current Chief Executive: Jeffrey Wolf
What is Heat Biologics?
Heat Biologics, Inc (NASDAQ: HTBX) is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials. (source)
Heat Biologics Revenue Totals
Heat Biologics annual revenue:
- 2019: $3.049 million
- 2018: $5.793 million
Heat Biologics annual net income:
- 2019: $20.384 million net loss
- 2018: $17.960 million net loss
Please note that some of these numbers are easier to find than others. A few of these Heat Biologics stats come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.